Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd + SRS in HER2+ Breast Cancer Brain Metastases
NCT07454668Phase 1Not yet recruiting
- Sponsor
- Baptist Health South Florida
- Start
- Jan 2027
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer and brain metastases, sponsored by Baptist Health South Florida. Primary endpoints: Dose-Limiting Toxicities at 3 weeks and Maximum Tolerated Dose at 3 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT07454668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454668.